CABALETTA BIO INC (CABA)
US12674W1099 - Common Stock
First Week of CABA June 21st Options Trading
Noteworthy Wednesday Option Activity: PINS, WYNN, CABA
Relative Strength Alert For Cabaletta Bio
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cabaletta Bio (NASDAQ:CABA) just reported results for the fourth quarter of 202...
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first...
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Noteworthy Friday Option Activity: PD, CABA, HOG
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Notable Thursday Option Activity: ISRG, CABA, NUVL
Cabaletta Bio stock gains on FDA fast-track tags for lead asset
Cabaletta Bio's (CABA) stock rose after the FDA granted additional fast-track designations for its lead candidate in autoimmune conditions. Read more here.
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Notable Tuesday Option Activity: CABA, BA, CMG
Cabaletta Bio Becomes Oversold (CABA)
Noteworthy Monday Option Activity: CABA, AVAV, ASTS
Cabaletta Bio GAAP EPS of -$0.37 beats by $0.04 (NASDAQ:CABA)
Cabaletta Bio reports Q3 2023 financial results, beating estimates with a GAAP EPS of -$0.37.
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first...